LCD-L36975
Document details
Summary
The new LCD for Bladder/Urothelial Tumor Markers from CGS, effective January 29, 2026, will impact how these tests are billed under Medicare. Providers will need to familiarize themselves with the updNew LCD for bladder tumor markers effective 01/29/2026.
Affected codes
ICD-10-CM
Affected specialty
Urology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36975&ver=24CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA125360 · Neurology
Xeomin (incobotulinumtoxinA) is an injectable botulinum toxin type A administered via injection, placing it squarely in the Medicare Part B pathway for physician-administered drugs. It is reimbursed u
View alertPolicy FDA-BLA761149 · Neurology
Enspryng (Satralizumab) is an injectable drug approved for Part B billing, likely leading to a new J-code assignment. With its status as an orphan drug, it may qualify for pass-through payment under M
View alertPolicy FDA-BLA761063 · Neurology
Emgality (galcanezumab) is likely to receive a new J-code for billing under Medicare Part B since it is an injectable drug. The drug may be eligible for ASP+6% reimbursement, given its injectable stat
View alertPolicy FDA-BLA761119 · Neurology
VYEPTI (Eptinezumab-JJMR) is an injectable medication likely to receive a J-code for billing under Medicare Part B. Its category may allow for ASP+6% reimbursement, but billing teams should confirm th
View alert